ArticleCell biochemistry and biophysics2026
Dioxopiperidinamide Derivative SKT-36 Alleviates scopolamine-induced Cognitive and Neurobehavioral Impairments in an In-vivo Zebrafish Model.
Article in Cell biochemistry and biophysics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dementia, characterized by cognitive decline and synaptic dysfunction, presents significant therapeutic challenges. This study explores the potential of SKT-36, a novel Dioxopiperidinamide (DOPA) derivative, in reversing scopolamine (SCP)-induced cognitive deficits in an in-vivo zebrafish model. SKT-36 exhibits high neuroprotective potential due to its inherent antioxidant and anti-inflammatory properties. Network pharmacology analysis revealed 637 intersecting targets linking SKT-36 with dementia-associated genes such as STAT3, GSK3B, and HSP90AB1 identified as key hubs. Molecular docking also confirmed highly favorable binding affinity of SKT-36 with Danio rerio of AChE, exhibited a binding energy of -6.58 kcal/mol. For in vivo analysis, zebrafish were treated with SKT-36 at 10 µM and 7.5 µM, and the effects were assessed using neurobehavioral, biochemical, and gene expression studies. SKT-36 at 10 µM significantly enhanced locomotor activity, reduced anxiety-like behavior, and improved spatial and recognition memory, as shown by various behavioral tests. Biochemically, SKT-36 reduced oxidative stress markers and restored antioxidant enzyme activities. Also, superior acetylcholinesterase (AChE) inhibitory activity compared to standard treatments was seen suggesting effective cholinergic modulation. Gene expression analysis indicated SKT-36’s anti-inflammatory and neuroprotective effects, normalizing genes related to inflammation and neuronal plasticity. Histological analysis confirmed reduced neuronal damage and amyloid-beta plaque accumulation observed in the optic tectum regions. These findings highlight SKT-36 as a promising therapeutic agent for dementia, offering neuroprotective and cognitive benefits.
Indexed as
Identifiers
41467933What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.